Hunt begins for new ValiRx CEO to drive growth

ValiRx plc, the Nuneaton-based life sciences company focusing on early-stage cancer therapeutics and women's health is on the hunt for a new CEO to lead the next stage of company growth. 

The current CEO, Dr Suzy Dilly, will remain in past until a new incumbent is found, which could take some months, the company said.

Dr Dilly said: "I've been honoured to play a leading role in establishing the new preclinically-focussed strategy for ValiRx in the period since my appointment in 2020, and as the company grows it is appropriate for an individual with experience of leading larger companies is sought to better serve the company's needs. 

"I remain committed to serving the best interests of our shareholders, our staff and collaborators, and will be available to provide support both to the search and to the integration of the incoming team members."

READ MORE: ValiRx signs agreement with Dundee University

In addition, Adrian de Courcey will join the ValiRx Board as a proposed Non-Executive Director, subject to completion of regulatory due diligence and Ray Horn will become a Board observer.